pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·1h ago·1 min read
save

Halloween edition of Endpoints Weekly teases Anthropic biotech acquisition and Jake Van Naarden’s deal strategy

Oct 31, 2026·read at Endpoints ↗Neutral

The latest Endpoints Weekly arrives with a Halloween theme, offering a light‑hearted introduction to the issue’s content.

Among the topics highlighted is Anthropic’s purchase of a one‑person biotech company, a move noted but not detailed in the preview.

The newsletter also references Jake Van Naarden’s dealmaking strategy, suggesting a focus on his approach to biotech transactions.

Readers are invited to sign up for full access to the article and additional newsletters for more in‑depth coverage.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “Anthropic’s one-person biotech buy; Jake Van Naarden’s dealmaking strategy; and more”

read at Endpoints ↗
86 words · retrieved 26m ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 19h agoSanofi may seek higher European drug prices, not withhold launches, under Trump dealEndpoints
  • 20h agoGilead CAR-T on partial clinical hold; Agios' PDUFA date pushed backEndpoints
  • 20h agoAstraZeneca says reorg could mean R&D cuts and trials shifted to emerging marketsEndpoints
  • 22h agoAnthropic's Nathan Frey on biopharma partners, M&A and pipelineEndpoints
  • 1d agoSanofi has 'no plans for major restructuring' as Dupixent's patent cliff loomsEndpoints